| Epilepsy |
1 |
1 |
| Cannabinoids |
0 |
0.99 |
| Child |
0 |
0.5 |
| Food and Drug Administration (FDA) |
0 |
0.44 |
| Adverse Effects |
0 |
0.25 |
| Seizure |
0 |
0.25 |
| Aminotransferase |
0 |
0.23 |
| Tuberous Sclerosis |
0 |
0.21 |
| Patient Safety |
0 |
0.2 |
| Clinical Guidelines |
0 |
0.19 |
| Toxicology |
0 |
0.14 |
| Diet |
0 |
0.13 |
| Drug Interaction |
0 |
0.13 |
| Epilepsy Surgery |
0 |
0.13 |
| Ketogenic Diet |
0 |
0.13 |
| Lennox-Gastaut Syndrome (LGS) |
0 |
0.13 |
| Liver Disease |
0 |
0.13 |
| Quality Control (QC) |
0 |
0.13 |
| Surgery |
0 |
0.13 |
| Addiction |
0 |
0.12 |
| Revenue and Practice Management |
0 |
0.1 |
| Adolescent Medicine |
0 |
0.06 |
| Anxiety |
0 |
0.06 |
| Brain |
0 |
0.06 |
| Chemotherapy |
0 |
0.06 |
| Clinical Pharmacology |
0 |
0.06 |
| Clinical Research |
0 |
0.06 |
| Dorsum |
0 |
0.06 |
| Financial Reimbursement |
0 |
0.06 |
| Impairment |
0 |
0.06 |
| Insurance |
0 |
0.06 |
| Liver |
0 |
0.06 |
| Metabolism |
0 |
0.06 |
| Nausea |
0 |
0.06 |
| Psychosis |
0 |
0.06 |
| Texas |
0 |
0.06 |
| Tolerance |
0 |
0.06 |
| TOR Inhibitor |
0 |
0.06 |
| Transdermal |
0 |
0.06 |
| Withdrawal Syndrome |
0 |
0.06 |
| Young Adult |
0 |
0.06 |
| Antibiotics |
0 |
0.05 |
| Anxiety Disorder |
0 |
0.05 |
| Diarrhea |
0 |
0.05 |
| Medical Marijuana |
0 |
0.05 |